Neumora Therapeutics, Inc. Common Stock
NMRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $129 | $125 | $127 | $142 |
| Short-Term Investments | $42 | $93 | $122 | $165 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $6 | $5 | $6 | $6 |
| Total Curr. Assets | $177 | $223 | $255 | $314 |
| Property Plant & Equip (Net) | $1 | $1 | $2 | $3 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $1 | $1 | $2 | $3 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $178 | $224 | $257 | $317 |
| Liabilities | – | – | – | – |
| Payables | $1 | $1 | $1 | $3 |
| Short-Term Debt | $0 | $0 | $1 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $25 | $20 | $26 | $25 |
| Total Curr. Liab. | $26 | $21 | $28 | $30 |
| LT Debt | $0 | $20 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $20 | $0 | $0 | $0 |
| Total NC Liab. | $20 | $20 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $1 | $1 | $2 |
| Total Liabilities | $46 | $41 | $28 | $30 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,125 | -$1,068 | -$1,015 | -$947 |
| AOCI | $0 | -$0 | -$0 | $0 |
| Other Equity | $1,257 | $1,251 | $1,244 | $1,234 |
| Total Equity | $132 | $183 | $228 | $287 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $178 | $224 | $257 | $317 |
| Net Debt | -$129 | -$105 | -$126 | -$140 |